Harmony Biosciences Holdings, Inc. (HRMY) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Harmony Biosciences is a neuroscience company focused on rare neurological diseases, primarily commercializing WAKIX (pitolisant) for narcolepsy. The company operates a single reportable segment and has expanded its pipeline through acquisitions of Zynerba Pharmaceuticals (2023) and Epygenix Therapeutics (2024), as well as new licensing agreements.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Product Revenue | $239.5M | $186.0M | $624.7M | $513.5M |
| Gross Profit | $179.8M | $143.3M | $494.9M | $411.1M |
| Gross Margin | 75.1% | 77.0% | 79.2% | 80.1% |
| Operating Income | $65.5M | $61.7M | $169.9M | $135.1M |
| Net Income | $50.9M | $46.1M | $136.2M | $96.0M |
| Diluted EPS | $0.87 | $0.79 | $2.32 | $1.66 |
| Cash & Investments | $778.4M (as of Sept 30, 2025) | |||
| Long-Term Debt (Net) | $148.5M (Principal: $170.0M) | |||
| Operating Cash Flow (9M) | $222.0M |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 28.7% YoY, driven by a 26.8% increase in units shipped and a 7.0% price increase implemented in January 2025. This was partially offset by higher rebates.
- R&D Expenses: Q3 R&D expenses surged 116.5% YoY to $55.0M. This was primarily due to a $15.0M IPR&D charge for a clinical milestone achieved for ZYN002 (Fragile X Syndrome) and increased clinical trial costs for EPX-100 and Pitolisant formulations.
- Cost of Sales: Increased 39.4% YoY, largely due to higher royalties triggered by increased net product revenue under the 2017 License Agreement with Bioprojet.
- Legal Settlements: The company reached settlement agreements with Lupin and Annora regarding ANDA litigation, allowing generic entry in January 2030.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing cash, cash equivalents, and investments ($778.4M) are sufficient to fund operations for at least the next 12 months.
- Pipeline Milestones:
- WAKIX: FDA approved for pediatric narcolepsy (EDS) in June 2024; resubmission for pediatric cataplexy occurred in Q3 2025.
- ZYN002: Phase 3 RECONNECT study for Fragile X Syndrome did not meet its primary endpoint due to high placebo response; next steps are under review.
- EPX-100: Phase 3 trials ongoing for Dravet Syndrome and Lennox-Gastaut Syndrome.
- Pitolisant GR/HD: Pivotal bioequivalence study for Pitolisant GR initiated in Q1 2025; data expected Q4 2025.
- Risks:
- Generic Competition: Multiple ANDA filings exist; settlements with Lupin and Annora set generic entry for Jan 2030, but other litigations (Novitium, Zenara, AET, MSN) remain pending with trial dates in 2026.
- Clinical Uncertainty: Failure of ZYN002 Phase 3 highlights risks in the neurobehavioral franchise.
- Regulatory: Pending FDA decisions on pediatric cataplexy and future approvals for new indications.
Investor Verification Checklist
- Verify the status of pending ANDA litigation against Novitium, Zenara, AET, and MSN, as these could impact patent exclusivity prior to the 2030 settlement date.
- Monitor the company's strategic decision-making regarding the ZYN002 program following the Phase 3 primary endpoint miss.
- Review the timeline for the Pitolisant GR pivotal study readout (expected Q4 2025) and subsequent PDUFA date (Q1 2027).
- Assess the impact of the $15.0M ZYN002 milestone payment on Q4 2025 cash flow and future royalty obligations.
- Confirm the progress of the pediatric cataplexy sNDA resubmission and FDA feedback.